Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment

Study ID
NCT01492127

Study type
Interventional

Study phase
Not Applicable

Study status
Unknown status

Trial Acronym

Trial Summary

This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC. The hypothesis of the study is that plasma proteasome levels will decrease following curative treatment, and that proteasome levels could be used as a marker to detect early recurrence.

More informations

Trial Starting Date

Dec 31,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit